DSpace JSPUI
DSpace preserves and enables easy and open access to all types of digital content including text, images, moving images, mpegs and data sets
Learn More
Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/23852| Title: | Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan |
| Authors: | Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı. Uludağ Üniversitesi/Tıp Fakültesi/Hemotoloji Anabilim Dalı. Ozan, Hakan Özkalemkaş, Fahir Ozan, Ülkü Özerkan, Kemal Bilgin, Tevfik Küçükyıldız, Faruk AAG-8495-2021 AAH-9791-2021 7003908072 6601912387 6507254632 6603345841 7004103925 6504371550 |
| Keywords: | Filgrastim Myelosuppression Prechemotherapy Topotecan Colony-stimulating factor Epithelial ovarian-Cancer Granulocyte Chemotherapy Carcinoma Invitro Invivo Cells Csf Oncology Obstetrics & gynecology |
| Issue Date: | 2001 |
| Publisher: | IMR Press |
| Citation: | Ozan, H. vd. (2001). "Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan". European Journal of Gynaecological Oncology, 22(6), 463-465. |
| Abstract: | Purpose: To investigate the efficacy and safety of single-dose filgrastim administered 24 hours prior to chemotherapy in the prevention of topotecan-related myeloid suppression. Methods: No medication was given to 21 rats in group I; 1.5 mg/m(2)/day topotecan was administered intraperitoneally for five days every three weeks to 21 rats in group 11; a single dose of 5 mug/kg filgrastim was injected intraperitoneally 24 hours before the intraperitoneal administration of the same dose of topotecan to 21 rats in group M. After completion of six cycles of chemotherapy, the rats were decapitated and blood samples were immediately collected into citrated tubes for complete blood counts. Results: White blood cell and lymphocyte counts in the control and the filgrastim + topotecan groups were similar (p > 0.05) and significantly higher than the counts in the topotecan group (p < 0.05). There was no difference in means of neutrophil, monocyte, eosinophil, basophil and erythrocyte counts among the groups (p > 0.05). Conclusion: Filgrastim administration prior to chemotherapy seems to be beneficial and further investigations are needed. |
| URI: | http://hdl.handle.net/11452/23852 |
| ISSN: | 0392-2936 |
| Appears in Collections: | Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.